Ignite Creation Date:
2024-05-06 @ 1:12 PM
Last Modification Date:
2024-10-26 @ 1:10 PM
Study NCT ID:
NCT03952806
Status:
COMPLETED
Last Update Posted:
2023-09-29
First Post:
2019-05-15
Brief Title:
Study of BHV-3241 in Participants With Multiple System Atrophy
Sponsor:
Biohaven Pharmaceuticals Inc
Organization:
Biohaven Pharmaceuticals Inc
Study Overview
Official Title:
Randomized Double-Blind Placebo-Controlled Parallel-Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects With Multiple System Atrophy M-STAR Study
Status:
COMPLETED
Status Verified Date:
2023-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
M-STAR
Brief Summary:
The purpose of this study is to compare the efficacy of verdiperstat BHV-3241 versus placebo in participants with Multiple System Atrophy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None